Table of Content

Open Access iconOpen Access

ARTICLE

Silencing of Btbd7 Inhibited Epithelial–Mesenchymal Transition and Chemoresistance in CD133+ Lung Carcinoma A549 Cells

Li-Zhou Fang*, Jian-Qing Zhang*, Ling Liu*, Wei-Ping Fu*, Jing-Kui Shu*, Jia-Gang Feng*, Xiao Liang

* Department of Respiratory Medicine, The First Affiliated Hospital of Kunming University of Science and Technology, Kunming City, Yunnan Province, P.R. China
† Department of Infectious Diseases, The First People’s Hospital of Yunnan Province, Kunming City, Yunnan Province, P.R. China

Oncology Research 2017, 25(5), 819-829. https://doi.org/10.3727/096504016X14772349843854

Abstract

Cancer stem cells (CSCs) are responsible for tumorigenesis and recurrence, so targeting CSCs is an effective method to potentially cure cancer. BTB/POZ domain-containing protein 7 (Btbd7) has been found in various cancers, including lung cancer and liver cancer, but the role of Btbd7 in non-small cell lung cancer (NSCLC), CSC self-renewal, and chemoresistance is still unknown. Therefore, in this study we found that the ratio of tumor sphere formation and stem cell transcription factors in CD133+ cells was dramatically enhanced compared to parental cells, which indicated successful sorting of CD133+ cells from A549. Meanwhile, Btbd7 and the markers of the epithelial–mesenchymal transition (EMT) process were more highly expressed in CD133+ cells than in parental cells. Silencing of Btbd7 significantly inhibited the self-renewal and EMT process in CD133+ cells. Furthermore, we found that downregulation of Btbd7 promoted cell apoptosis and increased the sensitivity to paclitaxel in CD133+ and parental cells. In conclusion, our results suggest that Btbd7 is a promising agent for the inhibition of survival and chemoresistance of cancer stem-like cells of NSCLC, which may act as an important therapeutic target in NSCLC.

Keywords


Cite This Article

APA Style
Fang, L., Zhang, J., Liu, L., Fu, W., Shu, J. et al. (2017). Silencing of btbd7 inhibited epithelial–mesenchymal transition and chemoresistance in cd133+ lung carcinoma A549 cells. Oncology Research, 25(5), 819-829. https://doi.org/10.3727/096504016X14772349843854
Vancouver Style
Fang L, Zhang J, Liu L, Fu W, Shu J, Feng J, et al. Silencing of btbd7 inhibited epithelial–mesenchymal transition and chemoresistance in cd133+ lung carcinoma A549 cells. Oncol Res. 2017;25(5):819-829 https://doi.org/10.3727/096504016X14772349843854
IEEE Style
L. Fang et al., "Silencing of Btbd7 Inhibited Epithelial–Mesenchymal Transition and Chemoresistance in CD133+ Lung Carcinoma A549 Cells," Oncol. Res., vol. 25, no. 5, pp. 819-829. 2017. https://doi.org/10.3727/096504016X14772349843854



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 33

    View

  • 29

    Download

  • 0

    Like

Share Link